Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre, Double-Blind, Randomised, Placebo-Controlled, Phase II/III Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy: Regeneration in Cervical Degenerative Myelopathy

Trial Profile

A Multi-centre, Double-Blind, Randomised, Placebo-Controlled, Phase II/III Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy: Regeneration in Cervical Degenerative Myelopathy

Planning
Phase of Trial: Phase II/III

Latest Information Update: 14 Aug 2018

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Spinal cord disorders
  • Focus Therapeutic Use
  • Acronyms RECEDE Myelopathy
  • Most Recent Events

    • 14 Aug 2018 New trial record
    • 06 Aug 2018 According to a MediciNova media release, this clinical trial is being conducted under an agreement between MediciNova, the University of Cambridge, and Cambridge University Hospitals NHS Foundation Trust. Funding for this clinical trial is being provided by the National Institute for Health Research (NIHR) in the United Kingdom (UK).MediciNova will provide the study drug supply, regulatory support, and safety monitoring support.
    • 06 Aug 2018 According to a MediciNova media release, the principal investigator for this is Dr. Mark Kotter, NIHR Clinician Scientist, Honorary Consultant in Neurosurgery at the University of Cambridge.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top